| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology/Experimental Medicine |
From the Université Paris Descartes (D.M.S., I.B., I.L., J.-P.D.-V.-H., J.E., M.V., M.A., P.G.), Paris; Inserm UMRS 765 (D.M.S., A.C., J.E., M.A., P.G.), Faculté de Pharmacie; AP-HP (D.M.S., S.G., J.-P.D.-V.-H., J.E., M.A., P.G.), Hôpital Européen Georges Pompidou; Inserm UMRS 745 (I.B., I.L., M.V.), Faculté de Pharmacie; Inserm UMRS 689 (J.-S.S.), Centre de Recherche Cardiovasculaire Lariboisière; Inserm Unité 833 (S.G.), Paris; Collège de France, Experimental Medicine Unit (S.G.), Paris; and Inserm UMRS 872 (J.-P.D.-V.-H.), France.
Correspondence to Prof Pascale Gaussem, Université Paris Descartes, Faculté de Pharmacie, INSERM UMRS 765, 4 Avenue de lobservatoire, F-75006 Paris, France. E-mail pascale.gaussem{at}egp.aphp.fr
Objective— Endothelial progenitor cells are currently identified either by their surface antigen expression or by their generation of early colonies in culture (CFU-Hill). Another population, endothelial colony-forming cells (ECFCs), has strong vessel-forming capacity but is less well characterized. Given the potential usefulness of CFU-Hill and ECFCs as cell therapy products, their thorough characterization is of major importance.
Methods and Results— CFU-Hill and ECFCs were expanded from human cord and adult blood. Bone morphogenetic proteins 2 and 4 (BMP2/4) were selectively expressed by ECFCs but not by CFU-Hill. The BMP pathway was involved in ECFC commitment and angiogenic potential in vitro. In vivo, BMP inhibition strongly reduced plug vascularization in bFGF-containing Matrigel plugs implanted in C57/Bl6 mice. Moreover, ECFC exposure to BMP increased their therapeutic potential in a nude mouse model of hindlimb ischemia. In amputation specimens from patients with critical leg ischemia who had received a local therapeutic injection of bone marrow mononuclear cells, newly formed vessels were strongly positive for BMP2/4, suggesting that endothelial cells involved in neovascularization have an ECFC-like phenotype.
Conclusion— BMP2/4 are a marker of ECFCs and play a key role in ECFC commitment and outgrowth during neovascularization.
We report that bone morphogenetic proteins 2 and 4 (BMP2/4) are selectively expressed by ECFCs but not by CFU-Hill. The BMP pathway is involved in ECFC commitment and angiogenic potential. Newly formed vessels observed after BM-MNC injection in patients with critical leg ischemia were strongly positive for BMP2/4.
Key Words: endothelial progenitor cells bone morphogenetic protein critical leg ischemia cell therapy neovascularization
This article has been cited by other articles:
![]() |
M. Toshner, R. Voswinckel, M. Southwood, R. Al-Lamki, L. S. G. Howard, D. Marchesan, J. Yang, J. Suntharalingam, E. Soon, A. Exley, et al. Evidence of Dysfunction of Endothelial Progenitors in Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., October 15, 2009; 180(8): 780 - 787. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Wang, S.-J. Lin, Y.-H. Chen, F.-Y. Lin, J.-C. Shih, C.-C. Wu, H.-L. Wu, and Y.-L. Chen Late Outgrowth Endothelial Cells Derived From Wharton Jelly in Human Umbilical Cord Reduce Neointimal Formation After Vascular Injury: Involvement of Pigment Epithelium-Derived Factor Arterioscler Thromb Vasc Biol, June 1, 2009; 29(6): 816 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Smadja, P. Gaussem, L. Mauge, D. Israel-Biet, F. Dignat-George, S. Peyrard, G. Agnoletti, P. R. Vouhe, D. Bonnet, and M. Levy Circulating Endothelial Cells: A New Candidate Biomarker of Irreversible Pulmonary Hypertension Secondary to Congenital Heart Disease Circulation, January 27, 2009; 119(3): 374 - 381. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |